SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-030469
Filing Date
2022-02-08
Accepted
2022-02-08 08:16:02
Documents
15
Period of Report
2022-02-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d311593d8k.htm   iXBRL 8-K 25340
2 EX-99.1 d311593dex991.htm EX-99.1 113338
3 EX-99.2 d311593dex992.htm EX-99.2 47324
7 GRAPHIC g311593snap0001.jpg GRAPHIC 3740
  Complete submission text file 0001193125-22-030469.txt   345241

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kpti-20220208.xsd EX-101.SCH 2853
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20220208_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20220208_pre.xml EX-101.PRE 11259
9 EXTRACTED XBRL INSTANCE DOCUMENT d311593d8k_htm.xml XML 3342
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 22599357
SIC: 2834 Pharmaceutical Preparations